High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$6.4M
$6,440,812
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| RXRX |
RECURSION PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2026-03-09 | $94,660 | S | Form 4 |
| RXRX |
RECURSION PHARMACEUTICALS, INC.
|
Director
10b5-1 Sell
|
2026-03-03 | $588,200 | S | Form 4 |
|
RXRX
S
RECURSION PHARMACEUTICALS, INC.
Gibson Christopher
• Director
10b5-1 Sell
2026-02-19
$138,400
|
||||||
| RXRX |
RECURSION PHARMACEUTICALS, INC.
|
Director
10b5-1 Sell
|
2026-02-19 | $138,400 | S | Form 4 |
| RXRX |
RECURSION PHARMACEUTICALS, INC.
|
CFO
10b5-1 Sell
|
2026-02-18 | $41,352 | S | Form 4 |
|
RXRX
S
RECURSION PHARMACEUTICALS, INC.
Gibson Christopher
• Director
10b5-1 Sell
2026-02-04
$164,800
|
||||||
| RXRX |
RECURSION PHARMACEUTICALS, INC.
|
Director
10b5-1 Sell
|
2026-02-04 | $164,800 | S | Form 4 |
| RXRX |
RECURSION PHARMACEUTICALS, INC.
|
Director
10b5-1 Sell
|
2026-02-03 | $924,000 | S | Form 4 |
|
RXRX
S
RECURSION PHARMACEUTICALS, INC.
Gibson Christopher
• Director
10b5-1 Sell
2026-01-20
$178,800
|
||||||
| RXRX |
RECURSION PHARMACEUTICALS, INC.
|
Director
10b5-1 Sell
|
2026-01-20 | $178,800 | S | Form 4 |
| RXRX |
RECURSION PHARMACEUTICALS, INC.
|
Director
10b5-1 Sell
|
2026-01-06 | $959,200 | S | Form 4 |
| RXRX |
RECURSION PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-12-19 | $180,000 | S | Form 4 |
| RXRX |
RECURSION PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-12-04 | $185,200 | S | Form 4 |
| RXRX |
RECURSION PHARMACEUTICALS, INC.
|
Director
10b5-1 Sell
|
2025-12-02 | $961,400 | S | Form 4 |
| RXRX |
RECURSION PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-11-19 | $166,400 | S | Form 4 |
| RXRX |
RECURSION PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-11-04 | $208,400 | S | Form 4 |
| RXRX |
RECURSION PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-10-23 | $570,000 | S | Form 4 |
| RXRX |
RECURSION PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-10-10 | $604,000 | S | Form 4 |
| RXRX |
RECURSION PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-09-25 | $476,000 | S | Form 4 |